IR 007Alternative Names: NeurOral
Latest Information Update: 17 May 2016
At a glance
- Originator Immune Response BioPharma
- Class Peptides
- Mechanism of Action Immunomodulators
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Multiple sclerosis
Most Recent Events
- 17 May 2016 Preclinical trials in Multiple sclerosis in USA (PO) before May 2016